Results for this period
First quarter1 January 2026–31 March 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The Industrial business recorded higher revenue and profit as orders received for industrial gas and LNG-related projects exceeded expectations, while execution of booked projects and the weaker yen also had a positive impact. The Aerospace business recorded higher revenue and profit on strong demand in the aircraft market and an industry-wide increase in production. In the Medical business, higher overseas sales, particularly in Europe, contributed to results, but profit declined slightly because of higher product development expenses and other costs.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–31 March 2026 |
| Net Sales | ¥55,366 million (YoY +14.6%) |
| Operating profit | ¥3,689 million (YoY +24.9%) |
| Ordinary income | ¥4,255 million (YoY +133.5%) |
| Profit attributable to owners of the parent | ¥3,156 million (YoY +39.4%) |
| Net income per share | ¥48.36 |
| Equity ratio | End of the current fiscal period 45.3 / End of previous period 44.2 |
| Total assets | ¥360,451 million |
| Net assets | ¥165,456 million |
| Cash flows from operating activities | ¥-5,612 million |
| Cash flows from investing activities | ¥-2,190 million |
| Cash flows from financing activities | ¥1,638 million |
| Cash and cash equivalents at end of period | ¥38,613 million |
| Full-year earnings forecast | Net Sales ¥233,500 million (YoY +8.3%) / Operating profit ¥16,500 million (YoY +7.6%) / Ordinary income ¥16,500 million (YoY -4.4%) / Net income ¥13,000 million (YoY -4.8%) |
| Annual Dividend Forecast | ¥40 → ¥50（+25.0%） |
| Segment revenue | Industrial business ¥36,552 million (YoY +23.8%) / Medical business ¥18,822 million (YoY +0.1%) |
| Segment profit | Industrial business ¥3,109 million (YoY +82.3%) / Medical business ¥1,635 million (YoY -5.7%) |
| Orders received and order backlog | Orders received ¥68,363 million / Order backlog Not disclosed |
| Depreciation and amortization | ¥2,898 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New Number of companies 0 companies / Company name Not disclosed / Excluded Number of companies 0 companies / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 69,175,664 shares |
| Treasury Shares at Period-End | 3,911,187 treasury shares |
| Factors Behind Changes in Business Performance | The Industrial business recorded higher revenue and profit as orders received for industrial gas and LNG-related projects exceeded expectations, while execution of booked projects and the weaker yen also had a positive impact. The Aerospace business recorded higher revenue and profit on strong demand in the aircraft market and an industry-wide increase in production. In the Medical business, higher overseas sales, particularly in Europe, contributed to results, but profit declined slightly because of higher product development expenses and other costs. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the Industrial business, orders received for industrial gas and LNG-related projects exceeded expectations. Execution of booked projects, the weaker yen and the solid performance of the industrial pumps and systems business contributed to higher revenue and profit. In the Aerospace business, revenue and profit increased on strong demand in the aircraft market and an industry-wide recovery in production. In the Medical business, overseas sales, particularly in Europe, increased, but profit fell slightly short of the year-earlier level because of higher product development expenses and other costs.